Ilex Medical Ltd (ILX.TA)
ILA 6322.0
(0.51%)
ILA 6322.0
(0.51%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 118.99 Million ILS | -34.89% |
| 2022 | 188.38 Million ILS | -40.62% |
| 2021 | 296.63 Million ILS | 57.31% |
| 2020 | 186.4 Million ILS | 59.74% |
| 2019 | 113.22 Million ILS | 25.78% |
| 2018 | 99.72 Million ILS | 20.89% |
| 2017 | 73.58 Million ILS | 21.73% |
| 2016 | 62.16 Million ILS | 4.13% |
| 2015 | 66.09 Million ILS | 9.5% |
| 2014 | 48.76 Million ILS | 25.52% |
| 2013 | 54.71 Million ILS | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 32.73 Million ILS | 4.04% |
| 2024 Q2 | 24.12 Million ILS | -17.83% |
| 2023 Q3 | 28.82 Million ILS | 0.27% |
| 2023 Q4 | 28.21 Million ILS | -2.12% |
| 2023 FY | - ILS | -34.89% |
| 2023 Q1 | 33.2 Million ILS | -31.19% |
| 2023 Q2 | 28.74 Million ILS | -13.42% |
| 2022 FY | - ILS | -40.62% |
| 2022 Q4 | 48.25 Million ILS | 22.52% |
| 2022 Q3 | 39.38 Million ILS | 72.89% |
| 2022 Q2 | 22.77 Million ILS | -70.79% |
| 2022 Q1 | 77.97 Million ILS | 30.69% |
| 2021 Q2 | 52.25 Million ILS | -22.77% |
| 2021 Q4 | 59.66 Million ILS | -51.49% |
| 2021 Q3 | 122.98 Million ILS | 135.37% |
| 2021 Q1 | 67.65 Million ILS | 61.05% |
| 2021 FY | - ILS | 57.31% |
| 2020 Q3 | 68.78 Million ILS | 40.83% |
| 2020 Q1 | 32.06 Million ILS | -24.29% |
| 2020 Q2 | 48.83 Million ILS | 52.33% |
| 2020 Q4 | 42.01 Million ILS | -38.92% |
| 2020 FY | - ILS | 59.74% |
| 2019 Q4 | 42.35 Million ILS | 47.24% |
| 2019 FY | - ILS | 25.78% |
| 2019 Q2 | 32.55 Million ILS | 16.08% |
| 2019 Q1 | 28.04 Million ILS | 9.93% |
| 2019 Q3 | 28.76 Million ILS | -11.63% |
| 2018 Q3 | 24.77 Million ILS | -5.37% |
| 2018 Q1 | 19.98 Million ILS | 39.13% |
| 2018 Q2 | 26.17 Million ILS | 31.0% |
| 2018 FY | - ILS | 20.89% |
| 2018 Q4 | 25.5 Million ILS | 2.98% |
| 2017 Q3 | 22.5 Million ILS | 7.58% |
| 2017 Q4 | 14.36 Million ILS | -36.19% |
| 2017 FY | - ILS | 21.73% |
| 2017 Q1 | 22.76 Million ILS | 63.48% |
| 2017 Q2 | 20.92 Million ILS | -8.09% |
| 2016 Q2 | 17.05 Million ILS | 28.14% |
| 2016 Q3 | 21.24 Million ILS | 24.55% |
| 2016 Q1 | 13.3 Million ILS | -24.56% |
| 2016 Q4 | 13.92 Million ILS | -34.45% |
| 2016 FY | - ILS | 4.13% |
| 2015 Q2 | 17.78 Million ILS | -10.07% |
| 2015 Q1 | 19.77 Million ILS | 648.89% |
| 2015 FY | - ILS | 9.5% |
| 2015 Q4 | 17.64 Million ILS | -9.31% |
| 2015 Q3 | 19.45 Million ILS | 9.4% |
| 2014 FY | - ILS | 25.52% |
| 2014 Q4 | -3.6 Million ILS | -112.39% |
| 2014 Q3 | 29.08 Million ILS | 108.09% |
| 2014 Q2 | 13.97 Million ILS | 64.96% |
| 2014 Q1 | 8.47 Million ILS | -43.31% |
| 2013 Q2 | 13.32 Million ILS | -5.88% |
| 2013 Q4 | 14.94 Million ILS | 34.68% |
| 2013 FY | - ILS | 0.0% |
| 2013 Q3 | 11.09 Million ILS | -16.69% |
| 2013 Q1 | 14.15 Million ILS | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|